Teva Biosimilar Medicines
Teva understands the future of biosimilars and the value they add to the healthcare system
We relentlessly pursue the development of biosimilar medicines to provide at-scale solutions where they are needed most.
Biosimilars are biologic medications that are highly similar to existing biologic medicines in terms of safety, efficacy, and quality, but are often more affordable. They are crucial in modern healthcare because they provide patients with cost-effective alternatives to biologic medications, increasing accessibility to vital treatments.
At Teva, we leverage our expertise in both high-quality complex generics and innovative medicines as well as partnering with leading developers to offer a wide range of high-quality biosimilars. This focus on biosimilars is a natural progression for us after leading the generic medicine industry for over 40 years.
Currently, Teva has:
18 assets in our biosimilar medicines pipeline
7 products expected to launch by 2027
We deliver biosimilars that meet rigorous regulatory standards and are highly similar to their reference biologic medication. Our comprehensive approach includes clinical research, robust quality control, and ongoing monitoring to ensure safety and efficacy to the highest standard.
Our Teva biosimilar portfolio covers a wide range of therapeutic areas, including oncology, autoimmune diseases, and other complex conditions. By offering high-quality biosimilars, we aim to contribute to a more sustainable healthcare system.
What’s the Difference Between Biologics and Biosimilars?
Understand the difference, and learn about Teva’s innovative work in this space
Teva’s dedication to biosimilars extends beyond product development. We educate healthcare professionals and patients about the importance of biosimilars and actively promote their acceptance and use. Additionally, we collaborate with healthcare organizations, regulatory bodies, and industry leaders to advance biosimilar development and adoption.
Bringing innovative and accessible biosimilar treatments to patients
A Brief History of Biopharmaceuticals
Join us on a journey that charts where biopharmaceuticals came from and where they may be going.
Join us on a journey that charts where biopharmaceuticals came from and where they may be going.
Discover the Magic of Biosimilars
Go behind the scenes at our lab to explore the processes involved in creating biosimilar medicines.
Go behind the scenes at our lab to explore the processes involved in creating biosimilar medicines.
Looking After the Little Things
Teva colleagues explain the science and complexities of producing biosimilars in simple terms.
Teva colleagues explain the science and complexities of producing biosimilars in simple terms.
NPS-ALL-NP-01501 MARCH 2025
